No more shots
A potential cure for Type 1 diabetes is on the horizon, and the novel approach would also allow Type 2 diabetics to stop insulin shots.
A potential cure for Type 1 diabetes is on the horizon, and the novel approach would also allow Type 2 diabetics to stop insulin shots.
The discovery increases the types of pancreatic cells that secrete insulin.
UT Health San Antonio researchers have a goal to reach human clinical trials in three years, but to do so they must first test the strategy in large-animal studies. Those studies will precede application to the Food and Drug Administration for Investigational New Drug approval, said Bruno Doiron, Ph.D., a co-inventor.
The scientists received a U.S. patent in January, and UT Health San Antonio is spinning out a company to begin commercialization.
The strategy has cured diabetes
in mice.
“It worked perfectly,” said Dr. Doiron, assistant professor of medicine. “We cured mice for one year without any side effects. But it’s a mouse model, so caution is needed. We want to bring this to large animals that are closer to humans in physiology of the endocrine system.”
Ralph DeFronzo, M.D., professor of medicine and chief of the Division of Diabetes, is co-inventor on the patent. “The pancreas has many other cell types besides beta cells, and our approach is to alter these cells so that they start to secrete insulin, but only in response to glucose [sugar],” he said. “This is basically just like beta cells.”
Insulin, which lowers blood sugar, is only made by beta cells. In Type 1 diabetes, beta cells are destroyed by the immune system and the person has no insulin. In Type 2 diabetes, beta cells fail and insulin decreases. At the same time in Type 2, the body doesn’t use insulin efficiently.
The therapy is accomplished by a technique called gene transfer. A virus is used as a vector, or carrier, to introduce selected genes into the pancreas. These genes become incorporated and cause digestive enzymes and other cell types to make insulin.
Gene transfer using a viral vector has been approved nearly 50 times by the FDA to treat various diseases, Dr. DeFronzo said. It is proven in treating rare childhood diseases, and good manufacturing processes ensure safety.
Unlike beta cells, which the body rejects in Type 1 diabetes, the other cell populations of the pancreas co-exist with the body’s immune defenses.
“If a Type 1 diabetic has been living with these cells for 30, 40 or 50 years, and all we’re getting them to do is secrete insulin, we expect there to be no adverse immune response,” Dr. DeFronzo said.
The therapy precisely regulates blood sugar in mice. This could be a major advance over traditional insulin therapy and some diabetes medications that drop blood sugar too low if not closely monitored.
“A major problem we have in the field of Type 1 diabetes is hypoglycemia [low blood sugar],” Dr. Doiron said. “The gene transfer we propose is remarkable because the altered cells match the characteristics of beta cells. Insulin is only released in response to glucose.”
People don’t have symptoms of diabetes until they have lost at least 80 percent of their beta cells, Dr. Doiron said.
“We don’t need to replicate all of the insulin-making function of beta cells,” he said. “Only 20 percent restoration of this capacity is sufficient for a cure of Type 1.”
